CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 7, 2010
Result type: Reports
Project Number: SR0204-000
Product Line: Reimbursement Review

Generic Name: Canakinumab

Brand Name: Ilaris

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Cryopyrin-Associated Periodic Syndrome

Indications: Cryopyrin-Associated Periodic Syndrome (CAPS)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: January 26, 2011

Recommendation Type: Do not list